Compass Pathways Plc (CMPS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Compass Pathways Plc (CMPS) has a cash flow conversion efficiency ratio of 0.715x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.79 Million) by net assets ($-52.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CMPS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Compass Pathways Plc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Compass Pathways Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Compass Pathways Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Compass Pathways Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PT Sarana Menara
JK:TOWR
|
0.152x |
|
Derichebourg
PA:DBG
|
0.205x |
|
Zhejiang Jolly Pharmaceutical Co Ltd
SHE:300181
|
-0.007x |
|
Tamilnad Mercantile Bank Limited
NSE:TMB
|
-0.323x |
|
Baosheng
SHG:600973
|
0.229x |
|
Develia S.A
WAR:DVL
|
0.028x |
|
KEDE Numerical Control Co Ltd
SHG:688305
|
0.028x |
|
PT Bank SMBC Indonesia Tbk
JK:BTPN
|
-0.083x |
Annual Cash Flow Conversion Efficiency for Compass Pathways Plc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Compass Pathways Plc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Compass Pathways Plc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-52.85 Million | $-157.24 Million | 2.975x | +486.18% |
| 2024-12-31 | $154.69 Million | $-119.19 Million | -0.770x | -78.61% |
| 2023-12-31 | $225.74 Million | $-97.38 Million | -0.431x | +25.85% |
| 2022-12-31 | $181.28 Million | $-105.45 Million | -0.582x | -144.21% |
| 2021-12-31 | $284.41 Million | $-67.75 Million | -0.238x | -13.15% |
| 2020-12-31 | $196.56 Million | $-41.38 Million | -0.211x | +89.93% |
| 2019-12-31 | $8.52 Million | $-17.81 Million | -2.091x | -406.57% |
| 2018-12-31 | $-14.37 Million | $-9.80 Million | 0.682x | -- |
About Compass Pathways Plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly … Read more